In this sense, miR-26a may well alleviate tumor angiogenesis of HCC via blocking HGF/c-MET pathway and it might be a novel therapeutic strategy for HCC patients with aberrant HGF and c-MET [88]. Here, HGF is linked to hepatocellular carcinoma.